Hematologic Oncology

November 17, 2020 - The review of the biologics license application for the CAR T-cell product lisocabtagene maraleucel for the treatment of adult patients with relapsed/refractory large B-cell lymphoma following at least 2 previous therapies has been delayed.

November 16, 2020 — The United Kingdom’s National Institute for Health and Care Excellence has recommended caplacizumab-yhdp with plasma exchange and immunosuppression for the treatment of an acute episode of acquired thrombotic thrombocytopenic purpura in adults and those aged 12 years and over who weigh at least 40 kg.

Deepa Jagadeesh, MD, discusses unmet needs in aggressive and rare lymphoma subtypes.

The treatment landscape of relapsed/ refractory multiple myeloma has undergone rapid changes over the past 2 decades, with over a dozen drug approvals by the FDA.

Ira Braunschweig, MD, discusses mitigating ​the toxicities that are associated with CAR T-cell therapy in lymphoma.

A Type II variation application has been submitted by Janssen Pharmaceutica NV to the European Medicines Agency for the subcutaneous formulation of daratumumab in combination with bortezomib, cyclophosphamide, and dexamethasone for use in adult patients with light-chain amyloidosis.

Naveen Pemmaraju, MD, discusses current treatment strategies in blastic plasmacytoid dendritic cell neoplasm.

The treatment landscape for multiple myeloma is poised to enter a new era of innovation with the development of therapies that target B-cell maturation antigen, which is highly expressed on plasma and MM cells.

Charles Schiffer, MD, discusses factors to consider for TKI discontinuation in chronic myeloid leukemia.

During the 2020 Institutional Perspectives in Cancer webinar on hematologic malignancies, Sudipto Mukherjee, MD, PhD, MPH, provides detail as to some of these nuances and the optimal management of patients with CML.

Delaying treatment for up to 7 days so that genomic data can be utilized to inform a personalized treatment approach is safe, feasible, and can improve overall survival in patients with acute myeloid leukemia.

Charles Schiffer, MD, discusses integration of TKIs, such as imatinib, into the chronic myeloid leukemia treatment paradigm.

Abhinav Deol, MD, highlights the progress that has been made with CAR T-cell therapy in leukemia and lymphoma, challenges faced with regard to accessibility and toxicity, and next steps for this modality.

Caron Jacobson, MD, discusses the significance of CD19-targeted CAR T-cell therapy in B-cell malignancies.

Jeffrey Zonder, MD, discusses the explosion of targeted therapies, along with the rise of cellular therapy, in hematologic malignancies.

Derek C. Galligan, MD, discusses unmet needs in high-risk multiple myeloma.